Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
Upturn AI SWOT - About
VanEck Biotech ETF (BBH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: BBH (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type ETF | Historic Profit 3.5% | Avg. Invested days 51 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | ETF Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Volume (30-day avg) - | Beta 0.76 | 52 Weeks Range 135.34 - 182.20 | Updated Date 06/30/2025 |
52 Weeks Range 135.34 - 182.20 | Updated Date 06/30/2025 |
Upturn AI SWOT
VanEck Biotech ETF
ETF Overview
Overview
The VanEck Biotech ETF (BBH) seeks to replicate as closely as possible the price and yield performance of the MVIS US Listed Biotech 25 Index, which tracks the overall performance of companies involved in the biotechnology field.
Reputation and Reliability
VanEck is a well-established ETF provider with a long history and strong reputation in the ETF market.
Management Expertise
VanEck has a dedicated team of professionals with expertise in ETF management and the biotechnology sector.
Investment Objective
Goal
To replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS US Listed Biotech 25 Index.
Investment Approach and Strategy
Strategy: The ETF employs a passive management strategy, aiming to track the MVIS US Listed Biotech 25 Index.
Composition The ETF holds a portfolio of stocks of publicly traded companies involved in biotechnology, focusing on 25 of the largest and most liquid US-listed companies.
Market Position
Market Share: BBH's market share is influenced by its AUM relative to other biotech ETFs.
Total Net Assets (AUM): 644000000
Competitors
Key Competitors
- iShares Biotechnology ETF (IBB)
- SPDR S&P Biotech ETF (XBI)
- ARK Genomic Revolution ETF (ARKG)
Competitive Landscape
The biotechnology ETF landscape is competitive with IBB dominating. BBH's concentrated portfolio offers potentially higher alpha but increased volatility. XBI offers a more diversified, equal-weighted approach. ARKG focuses on genomic revolution-related companies. Each ETF targets different risk-reward preferences.
Financial Performance
Historical Performance: Historical performance data is available from various financial data providers (e.g., Yahoo Finance, Bloomberg), but specific data is not provided here.
Benchmark Comparison: BBH's performance should be compared to the MVIS US Listed Biotech 25 Index to evaluate tracking effectiveness.
Expense Ratio: 0.35
Liquidity
Average Trading Volume
BBH generally exhibits good liquidity, with a healthy average trading volume facilitating ease of entry and exit for investors.
Bid-Ask Spread
The bid-ask spread for BBH is typically tight, indicating relatively low transaction costs.
Market Dynamics
Market Environment Factors
Biotech ETFs are influenced by factors such as FDA approvals, clinical trial results, healthcare policy changes, and overall market sentiment towards the biotech sector.
Growth Trajectory
BBH's growth is tied to the performance of the biotech industry. Changes to the underlying index methodology may also influence holdings.
Moat and Competitive Advantages
Competitive Edge
BBH focuses on the largest and most liquid US-listed biotech companies. Its concentrated portfolio offers targeted exposure to leading firms in the industry. It is strictly focused on biotechnology companies. This focus on well-established names may appeal to investors seeking lower relative risk compared to more broadly diversified or thematic biotech ETFs. This targeted approach to large cap biotech provides investors with alpha generation.
Risk Analysis
Volatility
BBH's volatility is expected to be high due to the inherent risks associated with the biotechnology sector.
Market Risk
BBH is exposed to market risk, particularly sector-specific risks such as clinical trial failures, regulatory hurdles, and patent expirations.
Investor Profile
Ideal Investor Profile
BBH is suitable for investors with a high-risk tolerance seeking targeted exposure to the biotechnology sector and willing to accept higher volatility for potentially higher returns.
Market Risk
BBH may be suitable for long-term investors with a positive outlook on the biotechnology industry, but less suitable for risk-averse investors or those seeking stable returns.
Summary
The VanEck Biotech ETF (BBH) offers focused exposure to leading US-listed biotechnology companies. Its concentrated portfolio aims to track the MVIS US Listed Biotech 25 Index. The ETF carries inherent sector risks, including clinical trial failures and regulatory challenges, resulting in potentially high volatility. BBH suits investors with a higher risk tolerance and a positive outlook on the biotech industry seeking targeted sector exposure.
Peer Comparison
Sources and Disclaimers
Data Sources:
- VanEck website
- ETF.com
- Yahoo Finance
- Bloomberg
Disclaimers:
This data is for informational purposes only and should not be considered investment advice. Past performance is not indicative of future results. Market share data is based on the AUM and may vary depending on the source and date.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About VanEck Biotech ETF
Exchange NASDAQ | Headquaters - | ||
IPO Launch date - | CEO - | ||
Sector - | Industry - | Full time employees - | Website |
Full time employees - | Website | ||
The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index includes common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.